Rebates were part of the controversial deal PhRMA struck with the White House and Senate Democrats during the healthcare debate of 2009 and 2010. Democrats agreed to leave rebates out of the healthcare legislation, and drug makers agreed to help finance key parts of the overhaul.
Adding rebates to Part D — effectively bringing Medicare payments closer to the much lower prices that Medicaid pays — would undermine the popular and successful Part D program, PhRMA stated.
Part D has cost the government 45 percent less than originally expected.
“The president’s proposal to tamper with a program that works well would not yield any benefit for seniors," PhRMA said. "Instead, analysts have projected that the president’s scheme would harm Part D’s competitive dynamics, yielding higher premiums, more restrictive access to medicines and diminished research on the next generation of medicines."